Riken Vitamin (4526) Fundamentals 2026 — P/E 13.3x, Revenue Analysis | SniperIQ
Riken Vitamin (4526) is a JP-listed Consumer Defensive company in Packaged Foods with a market capitalization of ¥92.4B, trading at ¥3165.00 on the JPX. This SniperIQ fundamentals page covers Riken Vitamin's valuation (P/E 13.3x, P/B 1.1x), profitability (net margin 7.3%), revenue (¥96.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Riken Vitamin's market cap?
Riken Vitamin (4526) has a market capitalization of approximately ¥92.4B, trading at ¥3165.00 on the JPX. Market cap moves with the live share price.
What is Riken Vitamin's P/E ratio?
Riken Vitamin's trailing twelve-month P/E ratio is 13.3x, with a price-to-book (P/B) of 1.1x. Valuation multiples are best compared with Consumer Defensive sector peers rather than read in isolation.
How profitable is Riken Vitamin?
Riken Vitamin runs a net profit margin of 7.3%, a gross margin of 30.9%, and an operating margin of 7.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Riken Vitamin generate?
Riken Vitamin reported revenue of ¥96.3B for fiscal year 2025, with net income of ¥7.0B and earnings per share (EPS) of 238.17. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Riken Vitamin pay a dividend?
Riken Vitamin offers a trailing dividend yield of about 3.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Riken Vitamin financially healthy?
Riken Vitamin carries a debt-to-equity ratio of 0.09x and a current ratio of 3.41x, with a market beta of 0.00. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Riken Vitamin a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Riken Vitamin (4526) the key facts are: market cap ¥92.4B, P/E 13.3x, revenue ¥96.3B, 52-week range 2662-3285. Weigh valuation, profitability, growth, and balance-sheet strength against Consumer Defensive peers and form your own view.
Track Riken Vitamin's full fundamentals live
Get Riken Vitamin's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.